MUC-1 conditional CD40 agonists
Bispecific binding proteins targeting MUC-1 and CD40 in tumor cells enhance anti-tumor immune responses by selectively activating CD40, addressing systemic toxicities and improving treatment efficacy for cancers.
WO2025257220A1 Publication Date: 2025-12-18MERCK PATENT GMBH
13 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2025/066182
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-24
- Filing Date
- 2025-06-10
- Publication Date
- 2025-12-18
AI Technical Summary
Technical Problem
Existing CD40 agonists for cancer treatment face limitations due to systemic toxicities and a narrow therapeutic window, necessitating improved strategies to enhance anti-tumor immune responses while minimizing off-tumor toxicity.
Method used
Development of bispecific binding proteins that selectively target MUC-1 and CD40, activating CD40 only in the presence of MUC-1 overexpressing tumor cells, combined with PD-1 inhibitors or chemotherapeutics to enhance anti-tumor activity.
Benefits of technology
The bispecific binding proteins induce potent CD40 modulation in tumor cells, reducing off-tumor toxicity and broadening the therapeutic window, leading to improved treatment outcomes for cancers like metastatic pancreatic ductal adenocarcinoma.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides bispecific binding proteins binding MUC-1 and CD40 and pharmaceutical compositions, and their use to upregulate cell-mediated immune responses and for the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art